Expert perspectives on the ecosystem of medical AI oversight in the GenAI era.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 42174156.
- Also identified by DOI 10.1038/s41746-026-02785-1 and PMC identifier 13197458.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this third article of a three-article series on interviews with Dr Shantanu Nundy, an advisor in the office of the Commissioner of the US FDA on AI governance and digital health policy, we explore how the oversight of generative AI (GenAI) and large language model (LLM)-enabled medical devices extends beyond the remit of any single regulator, requiring coordination among government agencies, health systems, and practicing clinicians. We also discuss practical advice for innovators seeking to engage productively with the FDA.